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No Association Between Hepatitis B
and Pancreatic Cancer in a Prospective
Study in Korea
TO THE EDITOR: We read with interest the report of a finding of
an association between hepatitis B infection and the risk of pancreatic
cancer in a large-scale case-control study by Hassan et al.1 They re-
ported a two- to three-fold increased risk of pancreatic cancer in those
who tested positive for hepatitis B core antibody (anti-HBc). The
authors suggested this was the first study to investigate an association
between this virus and pancreatic cancer. However, we published the
results of a large prospective cohort study of Koreans, which suggested
no association between pancreatic cancer and hepatitis B.2
In the Korean study, 664 patients were diagnosed with pancreatic
cancer after a median follow-up of 12 years, in a study population of
201,975 individuals with test results for hepatitis B surface antigen (HB-
sAg)status.ChronichepatitisBisendemicinKorea,andoverall,8%ofthe
study population tested positive for HBsAg. This figure was similar
among the patients with pancreatic cancer, resulting in an adjusted rela-
tive risk for HBsAg positivity of 1.13 (95% CI, 0.84 to 1.52). The cohort
consistedofKoreans insuredbytheNationalHealthInsuranceCorp,and
the HBsAg results were from a routine medical examination of the in-
sured workers conducted at study entry. Their dependents were not re-
quiredtoundergothismedicalexamination,whichiswhytestresultswere
only available for 32% of the total study population of 631,172.
In the study by Hassan et al,1 none of the patients, and only one
individual in the control group, tested HBsAg positive. The reported
association with pancreatic cancer pertained to anti-HBc rather than
to HBsAg positivity. They found a positive association in patients
testing anti-HBc positive/HBsAg positive, which indicates resolved
infection,3 and also in patients testing anti-HBc positive/HBsAg neg-
ative, which may indicate occult hepatitis B infection. Occult hepatitis
B viral infection occurs when chronically infected individuals do not
have detectable circulating HBsAg. However, in some individuals,
isolated anti-HBc positivity may indicate a false-positive test result
(ie, these individuals may never have been infected).4 Although the
serologic pattern reported by Hassan et al suggests occult infection,
formal diagnosis relies on demonstration of hepatitis DNA in serum
or liver tissue,5 which was not investigated.
HBsAg is a sensitive marker for chronic hepatitis B infection,3
and it is these chronic infections, rather than resolved or occult infec-
tions, that are associated with a high risk of developing hepatocellular
cancer.6 In a previous study in this Korean cohort, a strong associ-
ation between HBsAg and hepatocellular carcinoma was seen,6 and
the magnitude of increased risk was similar to that reported in prior
studies.7 It is not clear from a biologic viewpoint why resolved or
occult hepatitis B viral infection would be associated with elevated
pancreatic cancer risk, as suggested by the findings of Hassan et al,
when readily detectable chronic infection is not. Because of these
uncertainties, the potential association between hepatitis B viral infec-
tion and pancreatic cancer, although interesting, should currently be
interpreted with caution. Evaluation of pancreatic cancer specimens
for the presence of hepatitis B DNA would be a useful next step.
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IN REPLY: We appreciate the thoughtful comments of Ber-
rington de Gonzalez et al, who make two points related to our
recently published article.1 First, they state, “The authors suggested
that this was the first study to investigate an association between this
[hepatitis B] virus and pancreatic cancer.” In our report, we acknowl-
edged the work by Berrington de Gonzalez et al related to the associ-
ation between elevated liver enzymes and pancreatic cancer (cited as
reference 43). However, we did not comment on the authors’ report of
a nonsignificant association between hepatitis B virus (HBV) surface
antigen (HBsAg) and pancreatic cancer, because we believed that the
analysis of this association was a post-hoc analysis, and the study was
not designed to address the association between HBV infection and
pancreatic cancer. Our reasons for this belief were, first, pancreatic
cancer was diagnosed according to the International Statistical Classi-
fication of Diseases and Related Health Problems (C25, 10th revision;
WHO); thus, the study included patients with all types of pancreatic
neoplasms, including neuroendocrine and unspecified pancreatic
tumors, rather than just patients with pancreatic adenocarcinoma.
Second, patients with underlying liver diseases were excluded; thus,
there was no information about the viral status of these patients, nor
about the incidence of pancreatic cancer among these patients. Three,
data on HBsAg were missing for 68% of the study population. Fourth,
no information was provided regarding the laboratory methodology
used for HBsAg testing, or whether the HBsAg-positive results were
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